Cyclacel Pharmaceuticals Announces the Appointment of Brian Schwartz, M.D. as Chief Medical Officer

January 30, 2024

https://www.globenewswire.com/news-release/2024/01/30/2820102/10564/en/Cyclacel-Pharmaceuticals-Announces-the-Appointment-of-Brian-Schwartz-M-D-as-Chief-Medical-Officer.html

BERKELEY HEIGHTS, N.J., Jan. 30, 2024 (GLOBE NEWSWIRE) — Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC, NASDAQ:CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announced today that Brian Schwartz, M.D. will assume the role of interim Chief Medical Officer (“CMO”) of the Company effective immediately. Dr. Schwartz will succeed Mark Kirschbaum, M.D., whose employment was terminated by the Company.

Read more at globenewswire.com

Related news for (CYCC)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.